JP2024527001A5 - - Google Patents

Info

Publication number
JP2024527001A5
JP2024527001A5 JP2024504491A JP2024504491A JP2024527001A5 JP 2024527001 A5 JP2024527001 A5 JP 2024527001A5 JP 2024504491 A JP2024504491 A JP 2024504491A JP 2024504491 A JP2024504491 A JP 2024504491A JP 2024527001 A5 JP2024527001 A5 JP 2024527001A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
dose
aniflorumab
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527001A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/070860 external-priority patent/WO2023006700A1/en
Publication of JP2024527001A publication Critical patent/JP2024527001A/ja
Publication of JP2024527001A5 publication Critical patent/JP2024527001A5/ja
Pending legal-status Critical Current

Links

JP2024504491A 2021-07-27 2022-07-26 ループスの治療 Pending JP2024527001A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163225974P 2021-07-27 2021-07-27
US63/225,974 2021-07-27
US202163254663P 2021-10-12 2021-10-12
US63/254,663 2021-10-12
PCT/EP2022/070860 WO2023006700A1 (en) 2021-07-27 2022-07-26 Treatment of lupus

Publications (2)

Publication Number Publication Date
JP2024527001A JP2024527001A (ja) 2024-07-19
JP2024527001A5 true JP2024527001A5 (cg-RX-API-DMAC7.html) 2025-08-05

Family

ID=83059135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504491A Pending JP2024527001A (ja) 2021-07-27 2022-07-26 ループスの治療

Country Status (9)

Country Link
US (1) US20250326850A1 (cg-RX-API-DMAC7.html)
EP (1) EP4377349A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024527001A (cg-RX-API-DMAC7.html)
KR (1) KR20240038773A (cg-RX-API-DMAC7.html)
AU (1) AU2022317215A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226744A1 (cg-RX-API-DMAC7.html)
IL (1) IL310241A (cg-RX-API-DMAC7.html)
TW (1) TW202340245A (cg-RX-API-DMAC7.html)
WO (1) WO2023006700A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD1120170S1 (en) * 2024-03-28 2026-03-24 Karsten Manufacturing Corporation Golf club head

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
CN104603152A (zh) * 2012-06-13 2015-05-06 米迪缪尼有限公司 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途

Similar Documents

Publication Publication Date Title
EP4114465B1 (en) Anti-ifnar1 dosing regime for subcutaneous injection
TW202400234A (zh) 使用fcrn拮抗劑治療大疱性類天皰瘡之方法
AU2021356122B2 (en) Treatment of flares in lupus
JP2024518735A5 (cg-RX-API-DMAC7.html)
US20250002589A1 (en) Treatment of cutaneous lupus erythematous
TW202308691A (zh) 狼瘡性腎炎之治療
JP2024519196A5 (cg-RX-API-DMAC7.html)
JP2024516886A5 (cg-RX-API-DMAC7.html)
US20250002591A1 (en) Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients
KR20240038773A (ko) 루푸스의 치료
CN121127499A (zh) 狼疮的治疗
CN117337305A (zh) 系统性红斑狼疮患者中的1型干扰素受体抑制剂类固醇节制
JP2025533978A (ja) ループスの治療
EA052183B1 (ru) Лечение кожной красной волчанки
CN117677638A (zh) 狼疮的治疗
JP2023548848A (ja) ループスを処置するための方法および組成物
HK40087032B (en) Anti-ifnar1 dosing regime for subcutaneous injection
HK40087032A (en) Anti-ifnar1 dosing regime for subcutaneous injection